$ECOR 2ND QTR, RESULTS
RE;
electroCore to Announce Second Quarter Ended June 30, 2020 Financial Results on Thursday, August 13
August 6, 2020 at 4:05 PM EDT
Conference Call to be Held at 4:30pm Eastern Time
BASKING RIDGE, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2020 after the close of the market on Thursday, August 13, 2020. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.
Thursday, August 13 @ 4:30pm Eastern Time
Domestic: 877-407-4018
International: 201-689-8471
Conference ID: 13706874
Webcast: http://public.viavid.com/index.php?id=140717
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.
For more information, visit
http://www.electrocore.com.
Investors:
Hans Vitzthum
LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com
or
Media Contact:
Jackie Dorsky
electroCore
973-290-0097
jackie.dorsky@electrocore.com
RE;
electroCore to Announce Second Quarter Ended June 30, 2020 Financial Results on Thursday, August 13
August 6, 2020 at 4:05 PM EDT
Conference Call to be Held at 4:30pm Eastern Time
BASKING RIDGE, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2020 after the close of the market on Thursday, August 13, 2020. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.
Thursday, August 13 @ 4:30pm Eastern Time
Domestic: 877-407-4018
International: 201-689-8471
Conference ID: 13706874
Webcast: http://public.viavid.com/index.php?id=140717
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.
For more information, visit
http://www.electrocore.com.
Investors:
Hans Vitzthum
LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com
or
Media Contact:
Jackie Dorsky
electroCore
973-290-0097
jackie.dorsky@electrocore.com
Recent ECOR News
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 04/15/2026 08:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 08:05:06 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 08:01:02 PM
- electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 08:01:05 PM
- electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD • GlobeNewswire Inc. • 04/01/2026 12:00:00 PM
- electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 10:01:50 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/19/2026 09:22:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/19/2026 08:35:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:10:30 PM
- electroCore Announces Full Year 2025 Financial Results and Organizational Changes • GlobeNewswire Inc. • 03/19/2026 08:05:00 PM
- electroCore to Participate at the 38th Annual Roth Conference • GlobeNewswire Inc. • 03/10/2026 12:00:00 PM
- electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026 • GlobeNewswire Inc. • 03/09/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 09:30:06 PM
- Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”) • GlobeNewswire Inc. • 01/21/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 09:05:52 PM
- electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million • GlobeNewswire Inc. • 01/20/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 09:15:45 PM
- TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen • GlobeNewswire Inc. • 12/02/2025 01:00:00 PM
- electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum • GlobeNewswire Inc. • 11/10/2025 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2025 09:26:07 PM
